When Blood Sugar Looks Good But Isn't: A Critical Lesson About SGLT2 Inhibitors and Hidden Danger

A 45-year-old man with Type 1 diabetes developed a severe, life-threatening condition called euglycemic diabetic ketoacidosis (euDKA) while taking an SGLT2 inhibitor called ipragliflozin. The crisis was triggered by COVID-19, a common acute illness that increases metabolic stress.

What made this case striking: his continuous glucose monitor showed excellent control in the 48 hours before he arrived at the emergency room. His time-in-range was 71%—a level most people aim for—and his glucose readings were stable, with minimal variability. Yet when he arrived at the hospital severely ill, doctors found his blood pH was dangerously low (7.040, indicating severe acidosis) and he had significant ketones in his urine.

The patient made a critical decision during his illness: he stopped taking his basal (long-acting) insulin because his CGM readings looked fine. He assumed good blood sugar numbers meant his diabetes was under control and that insulin wasn't needed. He continued taking the SGLT2 inhibitor, however.

This combination created a dangerous situation. SGLT2 inhibitors work by flushing excess glucose into urine, which can lower blood sugar independently. Without insulin to maintain normal metabolism, and with the medication still active, his body shifted into a state of ketoacidosis—burning fat rapidly and producing dangerous levels of ketones—even though his glucose meter didn't reflect this crisis.

Euglycemic diabetic ketoacidosis is a rare but serious complication of SGLT2 inhibitors. The 'euglycemic' part means blood sugar remains near or within normal ranges, making the condition harder to spot. The ketoacidosis part—the actual metabolic emergency—can develop quietly in the background.

This case is one of the first to quantitatively document how strong CGM metrics can coexist with life-threatening euDKA. The patient's favorable glucose data masked the metabolic crisis unfolding in his blood chemistry.

If you take an SGLT2 inhibitor and have Type 1 diabetes, relying only on CGM readings during illness is not safe. Your blood sugar may look normal while your body produces dangerous ketone levels.

Blood ketone testing—checking ketones through a finger stick blood test, not urine—is a more direct way to catch euDKA early. Some insurance systems now cover these tests for people on SGLT2 inhibitors, though access varies widely and many patients and providers remain unaware of the option.

Symptoms matter more than numbers: nausea, vomiting, unusual tiredness, difficulty breathing, or stomach pain during illness warrant immediate medical evaluation, regardless of what your CGM shows. Never stop insulin without talking to your doctor, even if blood sugar looks stable.

This educational case highlights a gap between medical knowledge and real-world practice. While the risk of euDKA with SGLT2 inhibitors is well-established, many patients don't fully understand it, and access to preventive blood ketone testing remains limited. Structural barriers—like restrictions on test strip supplies—can prevent people from using this safety tool even when it's available.

Doctors and patients alike need clearer guidance on sick-day management, the limits of CGM data, and when to seek help. CGM technology is powerful and has transformed diabetes management, but this case shows it is not a complete picture of your metabolic health.

Source: Endocrine journal. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.